Valuation: CSL Limited

Market Cap 38.98B 34.27B 31.9B 29.3B 55.02B 3,739B 55.74B 379B 148B 1,846B 146B 143B 6,381B P/E 2026 *
-43.2x
P/E 2027 * 27.1x
Enterprise Value 47.71B 41.94B 39.04B 35.86B 67.33B 4,576B 68.22B 464B 181B 2,259B 179B 175B 7,809B EV / Sales 2026 *
3.1x
EV / Sales 2027 * 3.02x
Free-Float
99.3%
Yield 2026 *
3.5%
Yield 2027 * 3.59%
1 day+0.45%
1 week-3.68%
Current month+1.89%
1 month+1.32%
3 months-9.30%
6 months-35.12%
Current year-32.28%
1 week 113.75
Extreme 113.75
120.54
1 month 112.4
Extreme 112.4
126.98
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Buy

Director

1,036 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%-3.68%-56.79%-56.17% 38.25B
+1.70%-0.74%+18.48%-10.41% 66.74B
-0.08%+3.28%+37.97%+203.98% 53.32B
+1.78%+54.50%+54.50%+54.50% 48.12B
-1.01%+0.10%+52.17%-23.84% 29.85B
+1.02%+2.78%+69.33%+89.65% 23.51B
+2.89%-6.49%+62.90%-53.06% 21.45B
+0.12%+4.16%+81.68%+161.81% 16.47B
+1.44%+0.22%+65.12%+126.78% 16.38B
-1.09%+7.55%+136.41%+208.01% 12.4B
Average +0.72%+1.03%+52.18%+70.13% 32.65B
Weighted average by Cap. +0.86%+1.23%+37.82%+55.85%

Financials

2026 *2027 *
Net sales 15.37B 13.51B 12.58B 11.55B 21.69B 1,474B 21.98B 150B 58.4B 728B 57.71B 56.46B 2,516B 15.58B 13.69B 12.75B 11.71B 21.98B 1,494B 22.27B 152B 59.18B 738B 58.47B 57.21B 2,549B
Net income -974M -856M -797M -732M -1.37B -93.42B -1.39B -9.48B -3.7B -46.13B -3.66B -3.58B -159B 1.19B 1.04B 971M 892M 1.68B 114B 1.7B 11.55B 4.51B 56.21B 4.46B 4.36B 194B
Net Debt 8.73B 7.67B 7.14B 6.56B 12.32B 837B 12.48B 84.89B 33.15B 413B 32.76B 32.05B 1,428B 7.99B 7.03B 6.54B 6.01B 11.28B 766B 11.43B 77.74B 30.36B 378B 30B 29.36B 1,308B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-07-27 A$117.13 +0.63% 252,812
26-07-27 A$116.39 +1.90% 639,541
26-07-24 A$114.22 -1.32% 1,114,296
26-07-23 A$115.75 -1.86% 1,250,961
26-07-22 A$117.94 -2.83% 1,089,586
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
81.40USD
Average target price
96.99USD
Spread / Average Target
+19.14%

Quarterly revenue - Rate of surprise